Amedisys (AMED)
(Delayed Data from NSDQ)
$96.80 USD
-0.91 (-0.93%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $96.80 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.80 USD
-0.91 (-0.93%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $96.80 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
Zacks News
Illumina (ILMN) Grows on Innovation & Strategic Partnerships
by Zacks Equity Research
Illumina's (ILMN) alliances with Bristol-Myers Squibb and Loxo Oncology to reap positive results in oncology.
Here's Why You Should Invest in Baxter International Now
by Zacks Equity Research
Strategic buyouts consistently help Baxter (BAX) gain market traction. Recently, the company completes the consolidation of both RECOTHROM and PREVELEAK.
ResMed's (RMD) HEALTHCAREfirst Buyout to Boost SaaS Business
by Zacks Equity Research
Integration of HEALTHCAREfirst's solutions suite with ResMed's (RMD) SaaS portfolio will help manage the burgeoning population and provide benefits to patients.
Here's Why You Should Add ResMed (RMD) to Your Portfolio Now
by Zacks Equity Research
With a view to consistently lead the SDB market and boost the company's sales, ResMed (RMD) sets sights on product development and innovation.
Here's Why STERIS (STE) Stock is a Must Buy at the Moment
by Zacks Equity Research
STERIS (STE) gains ground on strategic buyouts and divestments.
Myriad Genetics' Planned Counsyl Buyout to Widen Portfolio
by Zacks Equity Research
Myriad Genetics (MYGN) plans to retain Counsyl as a wholly-owned subsidiary post the successful completion of the acquisition.
IDEXX's (IDXX) Catalyst Uptake Remains Strong & Boosts CAG
by Zacks Equity Research
Solid organic growth trend within IDEXX's (IDXX) CAG revenues to sustain on the back of a strong global placement of high-premium Catalyst instruments.
Abbott Presents Positive Data for AMPLATZER Amulet Device
by Zacks Equity Research
Abbott (ABT) proceeds with initiatives to boost the core Structural Heart division.
Abbott Presents Positive Study Results for Tendyne Device
by Zacks Equity Research
Abbott (ABT) leaves no stone unturned to drive its Structural Heart business.
Myriad Genetics' Prolaris Expands on New Coverage Decisions
by Zacks Equity Research
This increased rate in commercial insurer coverage for Myriad Genetics' (MYGN) Prolaris comes close on the heels of the NCCN guidelines.
Here's Why You Should Buy Boston Scientific (BSX) Stock Now
by Zacks Equity Research
Boston Scientific's (BSX) inorganic expansion plan bodes well for operational growth.
Abbott Gets FDA Nod for XIENCE Sierra, To Boost Vascular Wing
by Zacks Equity Research
Abbott (ABT) continues with the slew of developments in regards with the XIENCE Sierra coronary stent system.
Medtronic (MDT) Q4 Earnings: Can Spine Division Turn Around?
by Zacks Equity Research
Medtronic (MDT) expects to demonstrate positive outcome related to its distribution relationship with Mazor Robotics.
Zimmer Biomet New System Gets FDA Nod, to Boost Spine Wing
by Zacks Equity Research
Zimmer Biomet (ZBH) receives FDA's approval for the new system, which is likely to augment the company's lumbar spacers portfolio.
Cardiovascular Systems Rides on New Products Amid Tight Race
by Zacks Equity Research
Cardiovascular Systems (CSII) gains traction from a strong third-quarter fiscal 2018, witnessing a year-over-year revenue rise at both CAD and PAD businesses.
Will Solid Diabetes Arm Drive Medtronic's (MDT) Q4 Earnings?
by Zacks Equity Research
Medtronic (MDT) is poised to gain on strength in Diabetes business in Q4 on continued uptake of MiniMed 670G system in the United States along with enhanced sensor supply capacity.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
Illumina (ILMN) gains ground on product launches and international prospects.
Will Strong RTG Arm Drive Medtronic's (MDT) Q4 Earnings?
by Zacks Equity Research
Medtronic (MDT) is poised to gain on continued strength in RTG business in Q4.
Zacks.com featured highlights include: Louisiana-Pacific, Amedisys, MGM, Oshkosh and Federated National
by Zacks Equity Research
Zacks.com featured highlights include: Louisiana-Pacific, Amedisys, MGM, Oshkosh and Federated National
Amedisys or Chemed: Which is a Better Investment Choice?
by Zacks Equity Research
After considering various parameters and fundamentals, we help you make a choice between Amedisys (AMED) and Chemed (CHE).
Buy These 5 Low Leverage Stocks to Strengthen Your Portfolio
by Zacks Equity Research
With the Q1 earnings season in its last lap, we would recommend investors to avoid high-leveraged stocks, even if they are exhibiting solid earnings growth.
Can Amedisys (AMED) Stock Continue to Grow Earnings?
by Zacks Equity Research
Amedisys (AMED) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
Amedisys (AMED) Q1 Earnings, Revenues Beat on Overall Growth
by Zacks Equity Research
Robust growth in Medicare and non-Medicare revenues at Amedisys' (AMED) Home Health and Hospice divisions boost the company's Q1 results.
Healthcare Stocks' Earnings Due on May 7: EVHC, PINC & More
by Zacks Equity Research
Acute flu, aging population, increase in patient volumes and high claims would affect healthcare companies' Q1 earnings.
Amedisys (AMED) Up 1.9% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.